C difficile risk
Oral Bioavailability
IV: $$


6 mg/kg/dose IV over 60 minutes Q12H beginning within the first month of life

Note: Infuse over 60 minutes


10 mg/mL

Supplied by Pharmacy SMR as 10 mg/mL in D5W

24H Room Temperature

Neonatal: Creatinine >130 µmole/L or urine output <1 mL/kg/h: 6 mg/kg/dose IV Q24H

General Information


  • Baseline CBC with differential, serum creatinine, urea, AST, ALT, bilirubin

  • Bi-weekly during treatment: CBC with differential, liver function tests, serum creatinine and Urea

  • Monitor peripheral IV sites closely for phlebitis (highly irritating due to high pH)


  • Neutropenia (most common): In most cases interruption of therapy or reduction of the dose by 50% will result in increase in ANC in 3-7 days. If ANC <0.5x10⁹/L or if ANC does not increase after dose reduction, therapy should be discontinued until ANC >1x10⁹/L

  • Thrombocytopenia

  • Elevated liver function tests (AST, ALT, bilirubin)

  • Renal dysfunction

  • Hazardous Drug (high level) Considered to be a potential teratogen and carcinogen in humans. Use chemotherapy precautions when handling or disposing

  • 5 day per week dosing schedule allows patients to receive IV therapy as outpatients

  • Use valganciclovir orally as there is no oral formulation of ganciclovir. Note: valganciclovir can NOT be substituted for ganciclovir on a one-to-one basis

Route of Elimination: Neonatal: Renal as unchanged drug

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.